The investment was in the form of a convertible note, according to an April 20 news release. It will support the development of Remedisc, a therapeutic for the treatment of degenerative disc disease.
Pacira plans to make an additional $7 million investment based on future milestones. The investment follows Spine BioPharma’s recent series A financing round.
More articles on biologics:
Florida surgeon performs disc replacement on wrong area of patient’s spine
2 spine surgeon leaders exit Johns Hopkins
5 high-profile device company court battles: Medtronic, Smith+Nephew & more
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
